tetano
Editor, Senior Moderator
Int J Biol Macromol
. 2024 Jan 6:129259.
doi: 10.1016/j.ijbiomac.2024.129259. Online ahead of print. Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice
Jiaojiao Nie[SUP] 1 [/SUP], Yongfei Zhou[SUP] 2 [/SUP], Fan Ding[SUP] 2 [/SUP], Xiaoxi Liu[SUP] 2 [/SUP], Xin Yao[SUP] 2 [/SUP], Lipeng Xu[SUP] 2 [/SUP], Yaotian Chang[SUP] 2 [/SUP], Zeyu Li[SUP] 2 [/SUP], Qingyu Wang[SUP] 2 [/SUP], Li Zhan[SUP] 2 [/SUP], Lvzhou Zhu[SUP] 2 [/SUP], Kunpeng Xie[SUP] 2 [/SUP], Chenxi Li[SUP] 2 [/SUP], Yuhua Shi[SUP] 2 [/SUP], Qi Zhao[SUP] 3 [/SUP], Yaming Shan[SUP] 4 [/SUP]
Affiliations
The influenza A virus (IAV) is a ubiquitous and continuously evolving respiratory pathogen. The intranasal vaccination mimicking natural infections is an attractive strategy for controlling IAVs. Multiepitope vaccines accurately targeting multiple conserved domains have the potential to broaden the protective scope of current seasonal influenza vaccines and reduce the risk of generating escape mutants. Here, multiple linear epitopes from the matrix protein 2 ectodomain (M2e) and the hemagglutinin stem domain (HA2) are fused with the Helicobacter pylori ferritin, a self-assembled nanocarrier and mucosal adjuvant, to develop a multiepitope nanovaccine. Through intranasal delivery, the prokaryotically expressed multiepitope nanovaccine elicits long-lasting mucosal immunity, broad humoral immunity, and robust cellular immunity without any adjuvants, and confers complete protection against H3N2 and H1N1 subtypes of IAV in mice. Importantly, this intranasal multiepitope nanovaccine triggers memory B-cell responses, resulting in secretory immunoglobulin A (sIgA) and serum immunoglobulin G (IgG) levels persisting for more than five months post-immunization. Therefore, this intranasal ferritin-based multiepitope nanovaccine represents a promising approach to combating respiratory pathogens.
Keywords: Influenza A virus; Intranasal vaccination; Long-lasting mucosal immunity; Multiepitope nanovaccine; Self-adjuvant activity; Self-assembled ferritin.
. 2024 Jan 6:129259.
doi: 10.1016/j.ijbiomac.2024.129259. Online ahead of print. Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice
Jiaojiao Nie[SUP] 1 [/SUP], Yongfei Zhou[SUP] 2 [/SUP], Fan Ding[SUP] 2 [/SUP], Xiaoxi Liu[SUP] 2 [/SUP], Xin Yao[SUP] 2 [/SUP], Lipeng Xu[SUP] 2 [/SUP], Yaotian Chang[SUP] 2 [/SUP], Zeyu Li[SUP] 2 [/SUP], Qingyu Wang[SUP] 2 [/SUP], Li Zhan[SUP] 2 [/SUP], Lvzhou Zhu[SUP] 2 [/SUP], Kunpeng Xie[SUP] 2 [/SUP], Chenxi Li[SUP] 2 [/SUP], Yuhua Shi[SUP] 2 [/SUP], Qi Zhao[SUP] 3 [/SUP], Yaming Shan[SUP] 4 [/SUP]
Affiliations
- PMID: 38191112
- DOI: 10.1016/j.ijbiomac.2024.129259
The influenza A virus (IAV) is a ubiquitous and continuously evolving respiratory pathogen. The intranasal vaccination mimicking natural infections is an attractive strategy for controlling IAVs. Multiepitope vaccines accurately targeting multiple conserved domains have the potential to broaden the protective scope of current seasonal influenza vaccines and reduce the risk of generating escape mutants. Here, multiple linear epitopes from the matrix protein 2 ectodomain (M2e) and the hemagglutinin stem domain (HA2) are fused with the Helicobacter pylori ferritin, a self-assembled nanocarrier and mucosal adjuvant, to develop a multiepitope nanovaccine. Through intranasal delivery, the prokaryotically expressed multiepitope nanovaccine elicits long-lasting mucosal immunity, broad humoral immunity, and robust cellular immunity without any adjuvants, and confers complete protection against H3N2 and H1N1 subtypes of IAV in mice. Importantly, this intranasal multiepitope nanovaccine triggers memory B-cell responses, resulting in secretory immunoglobulin A (sIgA) and serum immunoglobulin G (IgG) levels persisting for more than five months post-immunization. Therefore, this intranasal ferritin-based multiepitope nanovaccine represents a promising approach to combating respiratory pathogens.
Keywords: Influenza A virus; Intranasal vaccination; Long-lasting mucosal immunity; Multiepitope nanovaccine; Self-adjuvant activity; Self-assembled ferritin.